Form D · Biotechnology
Clearmind Medicine Inc.
Vancouver, A1 · CIK 0001892500
Offering snapshot reported Feb 7, 2024 · SEC filing
- Reported sold
- $2.4M Offering amount: $2.4M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 11, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 7, 2024 | Initial | $2,400,000 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $192K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-504615
Common Shares, pre-funded warrants to purchase Common Shares
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Aegis Capital Corp. | 15007 |
Source: Form D, filed Feb 7, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Oz Adler | Director |
| Prof. Mark Haden | Executive |
| Asaf Itzhaik | Director |
| Alan Rootenberg | Executive |
| Yehonatan Shachar | Director |
| Amitay Weiss | Director |
| Dr. Adi Zuloff Shani | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
101 1220 West 6 Th Avenue
Vancouver, A1, V6H1A5
Vancouver, A1, V6H1A5